** Shares in Swiss-American eye care group Alcon ALCC.S drop 9.4% on revised 2025 outlook, impacted by U.S. tariffs, and Q1 results below estimates
** "This outlook incorporates a gross tariff impact of approximately $80 million, which is expected to pressure cost of net sales," the company said
** Alcon is more exposed than fields like cardiology, as ophthalmology procedures are often elective and can be delayed, said BTIG analyst Ryan Zimmerman ahead of results, commenting on U.S. impact, adding as well shares might be falling on recession fears
** The stock is on track for its worst day since March 2020, when it closed 10.6% lower
(Reporting by Anastasiia Kozlova)
((Anastasiia.Kozlova@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。